SPL Starpharma Holdings Ltd
- 0.097
- -0.002-2.02%
Starpharma Holdings Ltd News
Starpharma's DEP Irinotecan Shows Promising Efficacy in Phase 2 Advanced Cancer Trials
Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers.
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16%
Biopharmaceutical company Starpharma (ASX:SPL) entered into a strategic partnership with healthcare-focused investment firm Medicxi to co-found a new UK-based company called Petalion Therapeutics, aim
Starpharma Asked to Provide More Data for US FDA Approval of Vivagel
Starpharma Holdings (ASX:SPL) said the US Food and Drug Administration has demanded "additional" clinical efficacy data for the regulatory approval of the firm's VivaGel medication. The FDA ruling "do
Starpharma Says DEP Docetaxel Shows Positive Results From Clinical Trial
Starpharma Holdings (ASX:SPL) said DEP docetaxel showed positive results in the phase 2 clinical trial program. The drug demonstrated anti-tumor activity in multiple advanced, metastatic cancers, incl
Even After Rising 42% This Past Week, Starpharma Holdings (ASX:SPL) Shareholders Are Still Down 88% Over the Past Three Years
Starpharma Presents DEP Platform At Targeted Radiopharmaceuticals Conference in Berlin
Starpharma Holdings (ASX:SPL) presented the application of its DEP platform for precision cancer radiotheranostics at the Targeted Radiopharmaceuticals Summit Europe conference, scheduled to conclude
Starpharma Names CEO
Starpharma (ASX:SPL) appointed Cheryl Maley as its chief executive officer, effective Jan. 8, 2024, the biopharmaceutical firm said on Friday. Maley, who has more than 25 years of experience in the ph
Starpharma Secures AU$7 Million Tax Rebate for Fiscal Year 2023; Shares Rise 4%
Starpharma (ASX:SPL) secured AU$7.2 million rebate from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, the biopharmaceutical firm said on
Starpharma's Anti-Prostate Cancer Medication Shows Efficacy in Phase 2 Trials
Starpharma's (ASX:SPL) phase 2 trial for its cabazitaxel medication showed efficacy in its anti-tumor function for advanced, metastatic castrate-resistant prostate cancer cases, according to a Wednesd
Starpharma Presents DEP Irinotecan Clinical Data at AACR Meeting; Shares Jump 7%
Starpharma (ASX:SPL) provided a copy of the DEP irinotecan clinical poster, which highlights positive interim clinical data from the company's phase one/two clinical trial for the treatment of advance
Starpharma Completes Enrollment for COVID-19 Study
Starpharma (ASX:SPL) completed the enrollment phase for its ongoing clinical study investigating the use of the antiviral nasal spray Viraleze in patients with COVID-19, the pharmaceutical firm said o
AU Evening Wrap: Fortescue, BHP Rally as Iron Ore Breaches $US120/t
Paladin Energy jumped up 3.9%, and Deep Yellow gained 8.3%.
AU Morning Wrap: ASX Opens Higher; Myer Edges Up After FY23 Results
Stocks to watch: Starpharma, Yancoal, Myer.
AU Evening Wrap: ASX Closes 0.7% Lower as Tech Stocks Retreat
The tech sector ended 1.6% lower.
Starpharma (ASX:SPL) CEO Announces Resignation After 16 Years
Starpharma's [ASX:SPL] Viraleze Nasal Spray Receives Approval in Malaysia - Money Morning Australia
Starpharma (ASX:SPL) Secures VIRALEZE Regulatory Approval in Malaysia
Starpharma Holdings (ASX:SPL) Shareholders Have Endured a 60% Loss From Investing in the Stock Five Years Ago
Starpharma (ASX:SPL) Receives $7.1m R&D Tax Incentive Refund
Analysis
Price Target
No Data
